 WATERTOWN, Mass., Feb. 22, 2021 GLOBE NEWSWIRE -- Pandion Therapeutics, Inc. Nasdaq: PAND, a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today presented preclinical data on PT001, the Companys tissue-tethered PD-1 agonist, at the Network for Pancreatic Organ Donors with Diabetes nPOD 13th Annual Scientific Meeting. The research, done in collaboration with St Vincents Institute of Medical Research in Australia and funded by JDRF and the JDRF T1D Fund, showed that PT001 treatment delayed the onset of hyperglycemia in a mouse model of Type 1 diabetes. 